LEXEO THERAPEUTICS Trademark

Trademark Overview


On Wednesday, October 4, 2023, a trademark application was filed for LEXEO THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the LEXEO THERAPEUTICS trademark a serial number of 98209821. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Friday, May 31, 2024. This trademark is owned by Lexeo Therapeutics, Inc.. The LEXEO THERAPEUTICS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cardiovascular diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Friedreich's Ataxia; Pharmaceutical preparations for the treatment of arrhythmogenic cardiomyopathy; Pharmaceutical preparations for the treatment of hypertrophic cardiomyopathy; Pharmaceutical preparations for the treatment of central nervous system diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Alzheimer's disease; Pharmaceutical preparations for the treatment of Batten disease; Pharmaceutical preparations for the treatment of genetic diseases, disorders, and defects; Pharmaceutical preparations for the treatment of monogenic diseases, disorders, and defects; Gene therapy for the treatment of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for targeting underlying causes of diseases, disorders, and defects; Therapeutic agents for delivery of...
lexeo therapeutics

General Information


Serial Number98209821
Word MarkLEXEO THERAPEUTICS
Filing DateWednesday, October 4, 2023
Status641 - NON-FINAL ACTION - MAILED
Status DateFriday, May 31, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of cardiovascular diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Friedreich's Ataxia; Pharmaceutical preparations for the treatment of arrhythmogenic cardiomyopathy; Pharmaceutical preparations for the treatment of hypertrophic cardiomyopathy; Pharmaceutical preparations for the treatment of central nervous system diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Alzheimer's disease; Pharmaceutical preparations for the treatment of Batten disease; Pharmaceutical preparations for the treatment of genetic diseases, disorders, and defects; Pharmaceutical preparations for the treatment of monogenic diseases, disorders, and defects; Gene therapy for the treatment of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for targeting underlying causes of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for treatment of diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of cardiovascular diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of Friedreich's Ataxia; Pharmaceutical preparations for the detection or diagnosis of arrhythmogenic cardiomyopathy; Pharmaceutical preparations for the detection or diagnosis of hypertrophic cardiomyopathy; Pharmaceutical preparations for the detection or diagnosis of central nervous system diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of Alzheimer's disease; Pharmaceutical preparations for the detection or diagnosis of Batten disease; Pharmaceutical preparations for the detection or diagnosis of genetic diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of monogenic diseases, disorders, and defects; Gene therapy for the detection or diagnosis of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for detection or diagnosis of underlying causes of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for detection or diagnosis of diseases, disorders, and defects

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, October 13, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameLexeo Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10010

Trademark Events


Event DateEvent Description
Saturday, October 7, 2023NEW APPLICATION ENTERED
Friday, October 13, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, May 24, 2024ASSIGNED TO EXAMINER
Friday, May 31, 2024NON-FINAL ACTION E-MAILED
Friday, May 31, 2024NON-FINAL ACTION WRITTEN
Friday, May 31, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, August 28, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Wednesday, August 28, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED